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Abstract
Background—Influenza vaccines available for children in the United States include inactivated 
influenza vaccine (IIV) and live, attenuated influenza vaccine (LAIV). Objectives of this study 
were to quantify proportions of IIV and LAIV received by vaccinated children, and examine 
associations between vaccine type received and demographic characteristics.
Methods—National Immunization Survey-Flu (NIS-Flu) parental reported data for the 2011-12 
through 2013-14 influenza seasons were used to estimate proportions of vaccinated children 2-17 
years who received IIV and LAIV. Tests of association between vaccination type and 
demographic variables were conducted using Wald chi-square tests and pair-wise comparison t-
tests. Multivariable logistic regression was used to determine variables independently associated 
with receipt of LAIV versus IIV.
Results—In the 2013-14 season, 33.3% of vaccinated children received LAIV, similar to the 
proportion in the 2011-12 (32.2%) and 2012-13 (32.1%) seasons. Across all seasons studied, the 
strongest observed association was between vaccination type and child's age, with children 2-8 
years (Adjusted Prevalence Ratio (95% confidence interval) [APR(95% CI)] 1.41(1.27-1.56), 
1.46(1.34-1.59), and 1.50(1.38-1.63) for 2011-12, 2012-13, and 2013-14) and 9-12 years 
(APR(95% CI) 1.37(1.23-1.54), 1.38(1.26-1.51), and 1.50(1.38-1.63) for 2011-12, 2012-13, and 
2013-14) being more likely to have received LAIV than children 13-17 years. Among those 
vaccinated, whites were more likely to have received LAIV compared to blacks (APR(95% CI) 
1.19(1.05-1.35), 1.24(1.10-1.39), and 1.22(1.11-1.34) for 2011-12, 2012-13, and 2013-14), and 
children living above poverty (annual income >$75,000) were more likely to have received LAIV 
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than those living at or below poverty (APR(95% CI) 1.43(1.23-1.67), 1.13(1.02-1.26), and 
1.16(1.06-1.28) for 2011-12, 2012-13, and 2013-14).
Conclusions—This study provides a baseline of the extent and patterns of LAIV uptake that can 
be used to measure the impact of relevant public health policy. Additional research is needed to 
investigate parental and provider preferences and barriers regarding LAIV.
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Introduction
Influenza is a serious disease that can lead to hospitalization and death. Rates of influenza 
infection are highest among children, with children <5 years and especially those <2 years at 
high risk for complications, hospitalizations, and deaths [1-9]. Vaccination is the most 
effective strategy for preventing influenza infection and its potentially serious complications 
[10]. The Advisory Committee on Immunization Practices (ACIP) recommended influenza 
vaccination for children 6-23 months in 2004, expanded the age range to include children 
6-59 months in 2006, and further expanded the recommendation to include children 6 
months-18 years in 2008 [11-13].
Two types of influenza vaccine are available for children in the United States, inactivated 
influenza vaccine (IIV) and live, attenuated influenza vaccine (LAIV). IIV has been 
available for many years and is administered by intramuscular injection (i.e. a shot). A 
variety of IIV products are available from several different manufacturers. Age indications 
for IIV have no upper limit for children, but the lower limit varies by vaccine with some 
approved for children as young as 6 months [10;14]. LAIV first became available and 
recommended for use in healthy persons 5-49 years in 2003, and then expanded for use in 
healthy children 2-4 years in 2007 [15;16]. Only one LAIV product is available, and it is 
administered intranasally (i.e. the nasal spray) [10;14]. LAIV and IIV products were all 
trivalent, containing two influenza A and one influenza B viral antigens, until the 2013-14 
influenza season when trivalent LAIV was replaced by a quadrivalent LAIV formulation, 
containing an additional influenza B viral antigen, and IIVs became available in both 
trivalent and quadrivalent formulations [10]. At the June 2014 meeting, the ACIP voted to 
include a preference for the use, when immediately available and there are no 
contraindications, of LAIV for healthy children 2-8 years in their recommendations for the 
2014-15 influenza season based on studies that appeared to demonstrate superior efficacy of 
LAIV as compared with IIV among children, particularly younger children [17-20]. At the 
February 2015 meeting, the ACIP voted to remove this preferential recommendation when 
other study data showed that LAIV may not be superior to IIV [14;21].
The objectives of this study were to quantify the proportion of children vaccinated against 
influenza who received LAIV in recent seasons, and to examine associations between 
vaccine type received and demographic characteristics. The results of this study provide 
baseline data for vaccine policy considerations, and serve as essential input into vaccine 
impact, cost-effectiveness models, and vaccine safety analyses.
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Data from the National Immunization Survey-Flu (NIS-Flu) from 2011-2014 were analyzed 
to assess type of influenza vaccination received by vaccinated children 2-17 years during the 
2011-12, 2012-13, and 2013-14 influenza seasons [22]. The NIS-Flu is an ongoing, national 
list-assisted random-digit-dialed dual frame land line and cellular telephone survey of 
households with children. It includes three components: the NIS for children 19–35 months, 
the NIS-Teen for children 13–17 years, and the NIS child influenza module for children 6–
18 months and 3–12 years identified during the screening of households for the NIS and 
NIS-Teen [22-27]. Data were collected by parental report, and interviews conducted 
September through June for the 2011-12 season and October through June for the 2012-13 
and 2013-14 seasons from all 50 states and the District of Columbia were included in the 
analysis. The Council of American Survey and Research Organizations (CASRO) response 
rates ranged from 51.8%-63.4% for landline and 18.1%-33.5% for cellular telephones 
[28-31].
The NIS-Flu sample included 102,254, 107,550, and 130,409 children for the 2011-12, 
2012-13, 2013-14 seasons, respectively. The study sample used to examine LAIV uptake 
was limited to a subset of data (n=34,025, n=42,331, and n=55,256 for the 2011-12, 
2012-13, and 2013-14 seasons, respectively) that included children who were at least 2 years 
old (at October 1st of each season), had received at least one dose of influenza vaccine, and 
had information about influenza vaccination type available. Survey respondents were asked 
if their child had received an influenza vaccination and, if so, during which month and year; 
for vaccinated children with missing month and year of vaccination (2.3%, 6.3%, and 7.7% 
for the 2011-12, 2012-13, and 2013-14 seasons, respectively), this information was imputed 
from donor pools matched for week of interview, age group, state of residence, and race/
ethnicity. For children who received an influenza vaccination, respondents were asked “Was 
this a shot or the spray in the nose?”; children missing this information were excluded from 
the study (4.3%, 4.3%, and 5.7% for the 2011-12, 2012-13, and 2013-14 seasons, 
respectively). Information on child, maternal, and household socio-demographic 
characteristics were also collected during the NIS-Flu interviews.
Children were considered vaccinated if they were reported to have received an influenza 
vaccination August through May for the 2011-12 season and July through May for the 
2012–13 and 2013-14 seasons. State level and national influenza vaccination coverage 
estimates and methods were published previously for children 6 months and older, and were 
calculated for this study using the same methodology but for children who were at least 2 
years old (at October 1st) [22;29-31]. Tests of association between vaccination type received 
and demographic variables were conducted using Wald chi-square tests followed by pair-
wise comparison t-tests. Multivariable logistic regression was used to determine variables 
independently associated with receipt of LAIV versus IIV. The dependent variable in the 
multivariable model was receipt of LAIV, and independent variables included the following: 
child's age, sex, race-ethnicity, mother's education, poverty/annual household income, 
number of children in the household, urban-rural residence, region of residence, and 
vaccination facility type. Adjusted prevalence ratios (APR) based on predicted marginals 
from the logistic regression model are reported.
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Although some children in the study had received two doses of influenza vaccine in an 
influenza season, this study focused on the first (or only) dose received. A sub-analysis was 
done among children who received two doses in a season to quantify the consistency in 
vaccination type received, excluding those with missing information on vaccination type for 
one or both of their vaccinations (2.3%, 5.3%, and 2.8% for the 2011-12, 2012-13, and 
2013-14 seasons, respectively).
To assess accuracy of parental reported type of influenza vaccination, NIS and NIS-Teen 
parental and provider reported vaccinations during the study vaccination period for the 
2012-13 influenza season, the most recent available season, were summarized, and status 
over one or more vaccinations was classified as delivered by IIV only, LAIV only, or both 
IIV and LAIV for children with available type information. The sample for this analysis 
included children 2 years and older (at October 1st) with both a parent and provider reported 
influenza vaccination (n=2,685 for NIS and n=2,918 for NIS-Teen). Children were excluded 
if type information was missing (2.8% for NIS and 4.2% for NIS-Teen) or if type was 
reported as both IIV and LAIV (1.0% for NIS and 0.4% for NIS-Teen) from either source. 
The difference between the percent of children who received the nasal spray according to 
parental versus provider report was calculated.
A two-sided significance level of 0.05 was adopted for all statistical tests. Reported 
percentages and corresponding 95% confidence intervals (95% CI) were weighted, while 
reported sample sizes were unweighted. All analyses were weighted to population totals and 
to adjust for households having multiple telephone lines, unit non-response, and non-
coverage of non-telephone households. Analyses were conducted using SAS (version 9.3) 
and SUDAAN (version 11.0.0) statistical software to account for the complex design.
Results
The sample characteristics are presented in Table 1. The distribution across the various 
groups of children remained consistent for all three seasons studied.
National and state level estimates for receipt of LAIV by children 2-17 years are shown in 
Table 2 and Figure 1. In the United States, 33.3% of vaccinated children received LAIV and 
the rest (66.7%) received IIV during the 2013-14 season. At the state level, the proportion of 
children vaccinated during the 2013-14 season that received LAIV ranged from 20.6% 
(South Dakota) to 48.4% (North Dakota).
In bivariate analysis, child's age and race-ethnicity, mother's education, poverty status/
annual household income, number of children in the household, region of residence, and 
place of vaccination were all found to be associated with influenza vaccination type received 
across all three seasons studied (Table 3). Vaccinated children 2-8 years were more likely 
than children in the other age groups, such as 13-17 years, to have received LAIV (34.6%, 
35.4%, and 36.5% versus 24.7%, 24.2%, and 24.3% for the 2011-12, 2012-13, and 2013-14 
seasons, respectively). A higher percentage of whites received LAIV (37.0%) than blacks 
(28.1%), Hispanics (30.1%), and children of other or multiple races (28.5%), who all had 
similar proportions, in the 2013-14 season; racial/ethnic differences in influenza vaccination 
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type received remained constant across all seasons studied. Children of mothers who had at 
least a college degree were more likely to have received LAIV across all three seasons 
compared to children of mothers who were less educated. Children living in households 
above poverty with an annual income >$75,000 were consistently more likely to receive 
LAIV than children living in households above poverty with an annual income ≤$75,000, 
who were more likely to receive LAIV than children living at or below poverty. Children 
living in a household with only one child were less likely to receive LAIV than children 
living in households with multiple children. Across all seasons, fewer children living in the 
Northeast region received LAIV compared to the other regions. Finally, children who 
received their influenza vaccination at school were more likely to have received LAIV, 
especially compared to children who were vaccinated at a pharmacy. Influenza vaccination 
coverage estimates by selected characteristics related to the child and the child's household, 
are provided in Table 3.
The results of the multivariable analysis, presented in Table 4, were generally consistent 
with the bivariate analysis. The strongest association observed among vaccinated children 
across all three seasons was between vaccination type and child's age, with children 2-8 
years (APR 1.41, 1.46, and 1.50 for the 2011-12, 2012-13, and 2013-14 seasons, 
respectively) and 9-12 years (APR 1.37, 1.38, and 1.50 for the 2011-12, 2012-13, and 
2013-14 seasons, respectively) being more likely to have received LAIV than children 13-17 
years.
Among children who received two doses of influenza vaccination, we found that vaccination 
type remained consistent (IIV for both doses or LAIV for both doses) in the majority of 
these children (85.3%, 85.2%, and 82.4% for the 2011-12, 2012-13, and 2013-14 seasons, 
respectively). The percentages of children who received IIV for the first dose and LAIV for 
the second dose were 6.7%, 8.2%, and 9.3%, while the percentages of children who received 
LAIV for the first dose and IIV for the second dose were 7.9%, 6.6%, and 8.3% for the three 
seasons, respectively.
In the comparison of provider versus parent reported type of influenza vaccination for the 
2012-13 season, the percentage of vaccinated children 24-40 months (NIS) receiving LAIV 
was 17% by provider report and 22% by parent report. Based on NIS-Teen data, 28.4% and 
29.0% of vaccinated adolescents 13-17 years were reported to have received LAIV by 
provider versus parent report, respectively.
Discussion
This is the first study, to our knowledge, to estimate the proportion of influenza vaccination 
type received (LAIV vs. IIV) by children using a national sample. We found that 33.3% of 
children 2-17 years vaccinated against influenza received LAIV during the 2013-14 
influenza season, and that this proportion remained similar across all seasons studied. 
Although not representative of all children in the United States, a study of outpatient 
pediatric offices across the country, who provide influenza vaccination, also demonstrated 
that approximately 30% of vaccinated children received LAIV, during the 2008-2009 season 
[32]. In another study of immunization information systems (IIS) of 6 sentinel sites, which 
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contain approximately 10% of the U.S. population of children 2-12 years, exclusive use of 
LAIV among vaccinated children was reported to be 38.0% for children 2-8 years during the 
2013-14 influenza season, as compared to 36.5% of vaccinated children 2-8 years who were 
found to have received LAIV in this study [33].
As is typically seen with overall seasonal vaccination coverage estimates, we found that the 
proportion of vaccine type received varied considerably by state [29-31]. The estimated 
coverage rate for LAIV and IIV can be calculated for each state by multiplying the 
proportion of vaccinated children who received LAIV or IIV by the overall proportion of 
children who received an influenza vaccination. For example, the proportion of vaccinated 
children 2-17 years who received LAIV during the 2013-14 season in North Dakota was 
48.4%, and the proportion of children who were vaccinated against influenza was 61.8%. 
Therefore, the estimated coverage rate for LAIV in North Dakota was 29.9%; conversely, 
the estimated coverage rate for IIV was 31.8%. These LAIV and IIV coverage estimates are 
very different from those for South Dakota, 13.9% and 53.7%, respectively.
The strongest association observed in the study was between vaccine type and child's age. 
Younger children, 2-8 years and 9-12 years, were more likely to have received LAIV than 
older children, 13-17 years. It is likely that children prefer the nasal spray over receiving a 
shot. One study that utilized an Internet panel survey of children 8-12 years found that the 
majority of children would choose the nasal spray over a shot due to reasons such as an 
expectation of limited discomfort from the nasal spray, not liking shots, and the perception 
that the nasal spray is easier than a shot [34]. It could be assumed that younger children 
would also prefer the nasal spray to a shot, possibly even more. As children get older, they 
likely become less fearful and more tolerant of receiving shots. It's possible that providers 
may be more likely to offer LAIV to younger children, as opposed to adolescents, because 
of this. In addition, as mentioned previously, some earlier studies found LAIV to be superior 
to IIV for younger children, which may have influenced provider recommendation [17-20].
Another finding from our study was that children living in households with higher incomes 
(>$75,000) were more likely to have received LAIV than those living at or below poverty. 
This could be due to the higher cost of LAIV [35]. However, LAIV is available through the 
Vaccines for Children Program (VFC), a federally funded program that provides vaccines to 
children who might otherwise not be vaccinated due to inability to pay [36]. In addition, the 
Affordable Care Act (ACA) helps make preventive services, including routinely 
recommended immunizations, affordable and accessible for all Americans by requiring 
private health plans to cover and eliminate cost sharing for these services when given by an 
in-network provider [37].
We also found that white children were more likely to have received LAIV than black 
children. Our study did not address the reasons why a particular type of vaccine was 
selected. Although conjecture, it is possible that providers who serve a higher proportion of 
black children or low income children may be less likely to recommend and offer LAIV to 
their patients, and this could be due to a variety of reasons such as the cost of LAIV, 
availability of LAIV, storage capacity, the overall proportion of their patient population who 
are eligible to receive LAIV, and provider beliefs and attitudes regarding LAIV. It is also 
Kahn et al. Page 6













possible that parents of black or low income children may be less likely to choose LAIV due 
to safety concerns and a lack of knowledge regarding efficacy. A separate study is needed to 
verify these speculations. It is important for all providers, when possible, to offer a variety 
of influenza vaccines to help increase vaccination coverage. Furthermore, it is important for 
providers to effectively communicate with their patients regarding the safety and efficacy of 
LAIV and other influenza vaccines. Future studies are needed to address racial and 
socioeconomic differences in LAIV vaccination coverage.
With regard to place of vaccination, we found that the majority of children received their 
influenza vaccination at their doctor's office, and that 34.9% of those children received 
LAIV, similar to the overall proportion of vaccinated children (33.3%). One strategy known 
to increase influenza vaccination coverage, in general, is to expand access through the use of 
non-traditional settings for vaccination, such as pharmacies and school venues, to reach 
individuals who may not visit a traditional physician's office during the influenza season 
[38]. We found the highest proportion of children to receive LAIV was among those who 
received their vaccine in a school setting (54.2%), but only 5.4% of children were 
vaccinated at a school. A low proportion of children were found to receive LAIV at a 
pharmacy (15.3%), and only 4.6% of vaccinated children received their vaccination at a 
pharmacy. It is important for places where children are commonly vaccinated, and for non-
traditional settings such as pharmacies, to stock a variety of vaccine (LAIV and IIV) so that 
they can receive the most optimal or desirable vaccination.
This study is subject to the following limitations. First, type of influenza vaccination 
received was based on parental report, not validated with medical records, and, thus, is 
subject to recall bias. However, upon comparison, we found similar prevalence of LAIV 
based on provider and household reported data, with parental report possibly overestimating 
the share of vaccinations that were LAIV among the youngest children. Second, the NIS-Flu 
is a telephone survey and selection and non-response bias is possible and may remain even 
after weighting adjustments designed to reduce these types of bias. Third, we assessed 
influenza vaccination type for the first dose of vaccine administered, but some children 
received more than one dose. However, we found that the majority of children who received 
more than one dose of influenza vaccine received the same type of vaccination. Fourth, the 
NIS-Flu does not capture whether children have high risk conditions which would preclude 
them from receiving LAIV, and so we could not control for this in the model. This may 
partially explain the difference by age in the proportion of LAIV uptake, as older children 
are more likely to be diagnosed with chronic conditions, such as asthma [39].
The results of this study can be used to estimate LAIV use for children in the United States. 
The results of this study also provide baseline data that can be used to measure the impact of 
relevant public health policy. In addition, they can inform policy makers and other 
stakeholders of the socio-demographic characteristics associated with influenza vaccination 
type received by children, important in the development and tailoring of programs and 
messaging that will help to ensure that children receive the most optimal protection against 
influenza disease.
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APR Adjusted Prevalence Ratio
CI Confidence Interval
IIS Immunization Information Systems
VFC Vaccines for Children
ACA Affordable Care Act
MSA Metropolitan Statistical Area
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Figure 1. Influenza vaccination type among vaccinated children by state, United States, National 
Immunization Survey-Flu (NIS-Flu), 2013-14 influenza season
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Table 4
Association of receiving live, attenuated influenza vaccine (LAIV) (versus inactivated 
influenza vaccine (IIV)) with demographic characteristics among children 2 - 17 years 
vaccinated against influenza, United States, National Immunization Survey-Flu (NIS-Flu), 
2011-12 through 2013-14 influenza seasons
Characteristics
2011-2012 2012-2013 2013-2014
APR* ± 95% CI† APR ± 95% CI APR ± 95% CI
Child's age
 2 - 8 years 1.41 (1.27-1.56) 1.46 (1.34-1.59) 1.50 (1.38-1.63)
 9 - 12 years 1.37 (1.23-1.54) 1.38 (1.26-1.51) 1.50 (1.38-1.63)
 13 - 17 years Referent Referent Referent
Child's sex
 Male Referent Referent Referent
 Female 1.02 (0.95-1.10) 1.01 (0.96-1.07) 1.08 (1.02-1.13)
Child's race/ethnicity
 White, non-Hispanic 1.19 (1.05-1.35) 1.24 (1.10-1.39) 1.22 (1.11-1.34)
 Black, non-Hispanic Referent Referent Referent
 Hispanic 1.11 (0.96-1.29) 1.11 (0.96-1.28) 1.10 (0.98-1.23)
 Other, non-Hispanic 1.06 (0.90-1.23) 1.01 (0.87-1.17) 0.96 (0.84-1.08)
Mother's education
 < High school 0.97 (0.82-1.15) 1.07 (0.95-1.22) 1.02 (0.91-1.15)
 High school or equivalent 0.88 (0.78-0.99) 1.05 (0.95-1.17) 1.01 (0.92-1.11)
 Some college Referent Referent Referent
 ≥ College degree 1.02 (0.93-1.12) 1.22 (1.13-1.32) 1.19 (1.11-1.27)
Poverty/annual household income‡
 Above poverty (> $75,000) 1.43 (1.23-1.67) 1.13 (1.02-1.26) 1.16 (1.06-1.28)
 Above poverty (≤ $75,000) 1.33 (1.15-1.53) 1.06 (0.96-1.18) 1.07 (0.97-1.17)
 At or below poverty Referent Referent Referent
 Unknown 1.37 (1.15-1.63) 1.03 (0.90-1.18) 1.05 (0.93-1.18)
Number of children in household
 1 Referent Referent Referent
 2 - 3 1.10 (1.01-1.20) 1.24 (1.15-1.32) 1.23 (1.16-1.31)
 ≥ 4 1.29 (1.14-1.46) 1.34 (1.19-1.51) 1.31 (1.19-1.44)
Urban-rural residence
 Urban (MSA, principle city) 1.08 (0.97-1.20) 1.00 (0.92-1.09) 1.07 (0.98-1.17)
 Suburban (MSA, not principle city) 1.08 (0.98-1.20) 1.00 (0.92-1.08) 1.07 (0.99-1.16)
 Rural (non-MSA) Referent Referent Referent
Region of residence
 Northeast Referent Referent Referent
 Midwest 1.35 (1.23-1.48) 1.20 (1.11-1.31) 1.17 (1.10-1.26)
 South 1.36 (1.24-1.49) 1.25 (1.16-1.36) 1.20 (1.12-1.28)
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Characteristics
2011-2012 2012-2013 2013-2014
APR* ± 95% CI† APR ± 95% CI APR ± 95% CI
 West 1.16 (1.03-1.32) 1.15 (1.03-1.28) 1.12 (1.03-1.22)
Vaccination facility type§
 Medical Referent Referent Referent
 Non-medical 1.16 (1.04-1.29) 1.03 (0.95-1.12) 1.06 (0.99-1.14)
*
APR = Adjusted Prevalence Ratio. Estimates in bold are statistically significantly different from the referent (P < 0.05). All variables listed in the 
table were included in the model.
†
CI = Confidence Interval.
‡
Poverty level was defined based on the reported number of people living in the household and annual household income, and the U.S. Census 
poverty thresholds.
§
Place of vaccination was collapsed into two categories for the model: 1. Medical (doctor's office, hospital, clinic or health center/other medical), 
2. Non-medical (local health department, pharmacy or store, school, or other non-medical/work).
Vaccine. Author manuscript; available in PMC 2016 September 22.
